학술논문
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
Document Type
Article
Author
Zhao, F.-H.; Chen, W.; Pan, Q.-J.; Zhang, X.; Zhao, Y.-Q.; Xu, X.-Q.; Wu, T.; Huang, S.-J.; Yao, X.-M.; Guo, M.; Zhao, J.; Su, Y.-Y.; Li, S.-W.; Zhang, J.; Xia, N.-S.; Hu, Y.-M.; Chu, K.; Zhu, F.-C.; Wei, L.-H.; Zhao, C.; Li, M.-Z.; Li, M.-Q.; Wu, X.; Huang, W.-J.; Nie, J.-H.; Hong, Y.; Jiang, Y.-F.; Li, Q.; Tang, J.; Li, C.-H.; Guo, D.-P.; Ke, L.-D.; Lin, B.-Z.; Zheng, F.-Z.; Zhang, Q.-F.; Sun, G.; Pan, H.-R.; Li, Y.-M.; Qiao, Y.-L.
Source
In: The Lancet Infectious Diseases . (The Lancet Infectious Diseases, December 2022, 22(12):1756-1768)
Subject
Language
English
ISSN
14744457
14733099
14733099